Barnidipine

Drug Profile

Barnidipine

Alternative Names: Cyress; Hypoca; Libradin; Mepirodipine; Vasexten; YM 09730; YM 097305; YM 730

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; JE II Pharmaceutical; Korea Yamanouchi
  • Class Antihypertensives; Dihydropyridines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 14 Apr 2004 A study has been added to the adverse events and Hypertension therapeutic trials sections
  • 17 Sep 2002 Launched for Hypertension in Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top